The hormones that shape how a woman feels, sleeps, thinks, and metabolizes
Most women learn to recognize their own baseline long before they have a name for it. The energy that carries you through a working day without crashing. The sleep that restores you instead of merely interrupting consciousness. The libido that arrives without effort. The cognitive clarity that lets you hold several complicated thoughts at once. These feel like personality. They are largely biochemistry.
Then something changes. The shift can be slow, accumulating across months until you stop being sure which symptom appeared first. Or it can arrive suddenly after a stressful year, a surgery, a pregnancy, or the first irregularity in a cycle that has been predictable since adolescence. The energy thins. Sleep becomes lighter. Weight that used to respond to a careful week now ignores it. Mood softens at the edges in ways that are difficult to articulate.
What ties these changes together, almost always, is the same small group of hormones that has been running in the background the whole time.
At Katalyst Wellness in San Diego, the work of hormone therapy for women in San Diego begins with a clinical premise: estrogen, progesterone, and testosterone operate as a coordinated system. Understanding what each one does inside the female body, and how they influence one another, is the foundation of every protocol we build.
The three hormones at the center of female endocrine function
Estrogen, progesterone, and testosterone are the principal sex hormones in women, produced primarily by the ovaries with smaller contributions from the adrenal glands and peripheral tissues such as fat and skin. They are often discussed in a way that places estrogen at the center of menopause, treats progesterone as an accessory to estrogen, and leaves testosterone out of the female conversation entirely. That framing is both clinically incomplete and clinically consequential.
Each hormone has its own receptors throughout the body, including in the brain, bone, vasculature, skin, muscle, breast tissue, and reproductive organs. Each one influences metabolism, cognition, and mood in distinct ways. And each one declines on its own timeline, which is why a woman in her late thirties can have textbook estrogen levels and still feel symptomatic from a quiet drop in progesterone or testosterone that no one has measured.
Estrogen is the architect of female physiology
Estrogen is the dominant hormone of the follicular phase of the menstrual cycle and the hormone most directly associated with reproductive function. Its reach extends well beyond reproduction. Estrogen receptors are present in cardiovascular tissue, bone, the central nervous system, skin, urogenital tissue, and the gastrointestinal lining. When estrogen is adequate and stable, these systems function with a level of resilience that women often only appreciate retrospectively, once it begins to fade.
The most clinically relevant form of estrogen during the reproductive years is estradiol (E2). Estradiol supports endothelial function, maintains bone density through its effect on osteoclast activity, preserves vaginal and urethral tissue integrity, modulates serotonin and dopamine signaling, and protects insulin sensitivity in skeletal muscle. As estradiol declines through perimenopause and into menopause, the loss of these effects becomes measurable in bloodwork, on bone density scans, and in daily symptoms.
Common signals of low or fluctuating estrogen include hot flashes and night sweats, vaginal dryness, urinary frequency, joint stiffness, sleep fragmentation, brain fog, anxiety that feels new or amplified, and accelerated skin aging. Women who go through surgical menopause after an oophorectomy often experience these changes abruptly rather than gradually. Our team uses our comprehensive bloodwork diagnostics to establish where estradiol sits in the context of the rest of the endocrine system before any treatment decision is made.
Progesterone is the calming counterpart
Progesterone is the hormone of the luteal phase of the menstrual cycle and pregnancy, produced in significant amounts only after ovulation. Its role in female physiology is often reduced to endometrial protection, but its biological reach is much wider. Progesterone metabolites such as allopregnanolone bind to GABA receptors in the brain, producing a calming, sleep-supporting effect that explains why women often feel a sense of settledness in the days immediately after ovulation and why that calm can disappear in perimenopause when ovulation becomes inconsistent.
Progesterone also moderates estrogen activity at the receptor level, balances cortisol signaling, supports thyroid function, and influences fluid regulation. When progesterone declines without a corresponding decline in estrogen, the resulting state is sometimes described as estrogen dominance. This is one of the earliest hormonal shifts of perimenopause, and it tends to produce symptoms that are misattributed to stress: lighter and more interrupted sleep, heightened anxiety, breast tenderness, heavier or more clotted periods, premenstrual irritability that grows worse year after year, and a sense of being unable to fully relax even on rest days.
Because progesterone is the first ovarian hormone to decline in most women, often beginning in the late thirties, evaluating it in isolation rarely tells the full story. It must be interpreted against estradiol, against thyroid markers, and against the patient’s cycle pattern. Our overview of HRT for perimenopause and menopause in San Diego explains why this transition phase requires a more agile approach than a static post-menopausal protocol.
Testosterone is the hormone women are still rarely tested for
Women produce testosterone throughout their reproductive years, with levels typically peaking in the twenties and beginning a steady decline into the forties and fifties. By the time a woman reaches menopause, her testosterone production may be roughly half of what it was in her twenties, and that decline continues. Despite this, testosterone is still routinely omitted from standard female hormone panels, leaving a major contributor to energy, mood, libido, lean muscle mass, and cognitive sharpness completely unmeasured.
Testosterone receptors are present throughout the female body, including in the central nervous system, skeletal muscle, bone, breast tissue, and vascular endothelium. When testosterone is adequate, women report a particular quality of motivation, mental sharpness, physical strength, and sexual interest that is difficult to replicate through any other intervention. When it declines meaningfully, the loss often shows up first as a flatness of mood that does not respond to typical antidepressant approaches, alongside reduced exercise capacity and a libido that fades despite an otherwise satisfying relationship.
The clinical evidence base has caught up with what experienced hormone clinicians have observed for years. A systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology in 2019, pooling data from 36 randomized controlled trials involving 8,480 women, concluded that testosterone treatment significantly improves sexual function, including desire, arousal, pleasure, orgasm, and self-image, while reducing sexually-associated distress (Islam et al., The Lancet Diabetes & Endocrinology, 2019). This is the largest pooled analysis of testosterone therapy in women to date, and its implications extend beyond sexual function into the broader question of how seriously this hormone should be treated in female care.
How each hormone shows up
Symptom patterns rarely point cleanly to a single hormone. The table below summarizes the most common roles each hormone plays in female physiology and the signs that tend to appear when levels are insufficient.
|
Hormone |
Primary roles in the female body |
Common signs of insufficiency |
|---|---|---|
|
Estradiol (estrogen) |
Maintains bone density, supports cardiovascular and brain function, preserves vaginal and urethral tissue, stabilizes insulin sensitivity, modulates serotonin and dopamine |
Hot flashes, night sweats, vaginal dryness, painful intercourse, joint stiffness, fragmented sleep, brain fog, mood instability, accelerated skin and bone loss |
|
Progesterone |
Protects the endometrium, supports GABA-mediated calm and sleep architecture, balances estrogen at the receptor level, moderates cortisol, supports thyroid conversion |
Lighter or interrupted sleep, heightened anxiety, premenstrual irritability, breast tenderness, heavier or clotted periods, difficulty winding down |
|
Testosterone |
Supports libido and arousal, maintains lean muscle and bone, sharpens cognition and motivation, contributes to mood stability and confidence, influences metabolic rate |
Persistent fatigue, low libido, reduced exercise capacity, flat mood, slower recovery, loss of muscle tone despite consistent training, mental dullness |
Why the three hormones must be evaluated as a system
Hormones do not act in isolation. Estrogen sensitizes progesterone receptors. Progesterone moderates estrogen-driven proliferation. Testosterone interacts with estrogen through aromatase activity, the enzymatic pathway that converts a portion of circulating testosterone into estradiol in fat tissue and other peripheral sites. Sex hormone-binding globulin (SHBG) determines how much of each hormone is actually free and bioavailable, and SHBG itself is influenced by thyroid status, insulin levels, and oral estrogen exposure.
This interdependence means that a woman whose total testosterone looks adequate on paper may still be functionally low in testosterone if her SHBG has climbed, binding most of what she produces. A woman whose estradiol is in range may still be symptomatic if her progesterone has fallen far enough to produce a relative estrogen dominance. And a woman whose cortisol is chronically elevated may experience progesterone resistance at the receptor level even when her absolute progesterone reads within range.
This is why hormone optimization, done well, requires a panel that goes far beyond the three sex hormones themselves. Our breakdown of why we test over 60 biomarkers before and during HRT walks through exactly which markers we include and why each one matters for interpretation.
|
What a complete female hormone evaluation should include. A useful panel measures estradiol, progesterone, total and free testosterone, SHBG, DHEA-S, a full thyroid profile including free T3 and free T4, fasting insulin and glucose, vitamin D, inflammatory markers such as hs-CRP, and liver and kidney function. Anything narrower leaves clinically meaningful gaps in interpretation. |
How life stage changes the priority order
The clinical question is rarely whether to treat estrogen, progesterone, or testosterone in the abstract. It is which hormone has shifted first, by how much, and against what backdrop. Life stage shapes that answer.
Late reproductive years (mid-thirties through early forties). Progesterone is typically the earliest hormone to decline. Cycles may still appear regular while ovulation becomes less reliable, which lowers the progesterone produced in the luteal phase. Women in this window often present with worsening premenstrual symptoms, lighter sleep, and a creeping anxiety that has no obvious external cause. Estradiol and testosterone may still be in healthy ranges at this stage.
Perimenopause (typically forties into early fifties). Estradiol begins to fluctuate erratically, sometimes surging well above premenopausal baselines before dropping sharply. Progesterone continues its decline. Testosterone follows a steadier downward trend. This is the phase that produces the widest spectrum of symptoms, because the body is responding to a hormonal environment that changes from week to week rather than settling into a new state.
Menopause and beyond. Ovarian estradiol production drops to a small fraction of premenopausal levels, progesterone production from the ovaries effectively ceases, and testosterone continues its gradual decline. Symptoms often consolidate around vasomotor changes, vaginal and urinary atrophy, bone loss, cardiovascular shifts, and a metabolic environment that favors abdominal fat storage. This is the stage at which structured hormone therapy can have the most dramatic impact on quality of life and long-term health markers.
Surgical menopause. When the ovaries are removed before natural menopause, all three hormones drop sharply at the same time. The clinical picture is more abrupt, and the case for early evaluation is stronger because the body has not had time to adapt gradually.
What clinical optimization actually involves
Optimization is a structured process rather than a prescription handed out on the first visit. At Katalyst Wellness, every patient begins with a complete metabolic and hormonal evaluation, reviewed by our physician in a dedicated consultation. The treatment plan is built from the entire data set rather than from a narrow snapshot of sex hormones.
Where hormone replacement is indicated, the protocol uses bioidentical preparations selected for their molecular match to the hormones the body produces endogenously. Dosing is conservative at the outset and adjusted based on follow-up bloodwork rather than on guesswork. The bioidentical hormone replacement therapy in San Diego that we offer is delivered alongside ongoing monitoring, because the dose that is correct in month one frequently needs refinement by month six as the body adapts.
In some cases, the answer is not hormone replacement at all, or not yet. A woman whose thyroid is underperforming, whose insulin resistance has progressed quietly, or whose inflammatory load is interfering with hormone receptor sensitivity may need those issues addressed before or alongside any sex hormone intervention. This is why a complete diagnostic foundation matters more than any single therapy.
Why hormone therapy is only as effective as the body it is delivered into
Hormones produce their effects by binding to receptors and triggering downstream cellular activity. That activity depends on the metabolic environment of the cell itself. Two women with identical estradiol levels can experience very different responses to the same dose depending on their cortisol patterns, their thyroid status, and the energy production capacity of their mitochondria.
Chronic inflammation, in particular, blunts hormone receptor sensitivity. A woman with elevated hs-CRP and unaddressed gut inflammation may have her estradiol restored to an excellent range and still feel sub-optimal because the receptors are not responding the way they should. In these cases, layering in interventions such as low dose naltrexone therapy in San Diego often unlocks the response that hormone therapy alone could not produce. Cellular energy is another frequent limiting factor, which is why combining NAD+ with HRT can be particularly useful for patients whose labs look optimized but whose symptoms have not fully resolved.
The metabolic side of female hormone optimization
Hormones and body composition exist in a reciprocal relationship. Estrogen supports insulin sensitivity, progesterone moderates fluid balance, and testosterone preserves the lean muscle mass that drives resting metabolic rate. When all three decline, the metabolic terrain becomes less forgiving, and the energy required to maintain a stable weight increases. For women in whom this shift has already taken hold, layering in medical weight loss in San Diego alongside hormone optimization addresses both sides of the equation.
Two markers in particular deserve attention alongside sex hormones during female evaluation:
- Fasting insulin. Insulin resistance often precedes glucose abnormalities by years. A woman can have a textbook fasting glucose value while her fasting insulin is climbing steadily, and the metabolic consequences accumulate during that silent phase.
- Free T3. TSH alone misses a significant proportion of women with sluggish thyroid output. Free T3 is the active thyroid hormone at the cellular level, and its conversion from T4 is influenced by cortisol, inflammation, and selenium status, all of which shift during the perimenopausal transition.
|
Your hormones deserve a complete reading. If you have been told your labs are normal but you still do not feel like yourself, the panel may simply not have been complete. Book a consultation with Katalyst Wellness in San Diego and let our clinical team, led by Dr. Camhi, evaluate the full hormonal and metabolic picture before any treatment recommendation is made. |
Frequently asked questions
Do I need to be in menopause to benefit from hormone optimization?
No. Hormonal shifts begin years before menopause for most women, often starting with progesterone decline in the late thirties. Symptoms that emerge during the perimenopausal transition frequently respond well to clinical intervention, and earlier evaluation tends to produce better outcomes than waiting until symptoms become severe.
Why is testosterone not included in most standard female hormone panels?
Conventional gynecological care has historically focused on estrogen and progesterone, with testosterone treated as a male concern. Clinical understanding has evolved well ahead of standard practice, and current evidence supports the routine inclusion of total and free testosterone alongside SHBG in any meaningful female evaluation.
Is bioidentical hormone therapy safe?
Bioidentical hormone therapy, when prescribed at appropriate doses and monitored with regular bloodwork, has a well-established safety profile for healthy women without contraindications. The relevant variables are dose, delivery method, individual risk factors, and the rigor of follow-up. Risk increases when therapy is delivered without proper evaluation or ongoing monitoring.
How long before I notice a difference after starting treatment?
Sleep and mood often respond within the first two to four weeks. Energy and cognitive clarity tend to follow over the next one to two months. Body composition changes, libido improvements, and the more subtle benefits to skin and joint comfort generally emerge over three to six months as the protocol is refined.
What if my symptoms persist even after my hormone levels look optimal on paper?
This is a common scenario and almost always points to a contributing factor outside the sex hormones themselves. Thyroid conversion, cortisol patterns, inflammatory load, nutrient status, and cellular energy production all influence how well hormones can act once they reach their receptors. A complete reassessment usually identifies what is interfering.
References
Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology, 7(10), 754-766. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30189-5/fulltext
The Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. https://doi.org/10.1210/jc.2015-2236
